HitGen has established its own capabilities for early stage research & discovery of small RNA drugs. As shown below, we have assembled a group of experts and talents in the field to substantially support RNA interference (RNAi)-based therapeutics development from initial RNA design to preclinical candidate nomination (PCC) stage, including RNA bioinformatics, oligonucleotide chemistry, in vitro and in vivo functional evaluation. Endorsed by our intensive experience in the DNA-Encoding Library (DEL) technology and Nucleic Acid Chemistry, we are able to provide comprehensive and one-stop services, such as target survey analysis, rational design of highly potent small RNAs, a wide variety of phosphoramidites, synthesis and chemical modification/conjugation of various nucleic acids, process development, functional screening in in vitro cell culture as well in vivo animal models.
HitGen will attend the meeting and the interactive event offers scientific and networking opportunities for those working in drug research and development.
To oarrange a meeting with HitGen, please call +86-28-85197385, +1-508-840-9646
For media inquiries: firstname.lastname@example.org
For investor inquiries: email@example.com
For business development: firstname.lastname@example.org
Building C2, NO.8, Huigu 1st East Road
Tianfu International Bio-Town,
Shuangliu District, Chengdu City,
Sichuan Province,P.R. China
Tel : +86-28-8519-7385
HitGen Pharmaceuticals Inc.(US Subsidiary)
Tel : +1-(508)-840-9646
Granta Park,Great Abington
Tel : +44(0)1223-895555